Atovaquone with radiation for children with brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests adding atovaquone to standard radiation therapy for children with aggressive brain tumors like high-grade glioma (a fast-growing brain cancer) or medulloblastoma. The goal is to see if this drug, which targets energy production in cancer cells, can make radiation work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 25 years old, weigh more than 22 pounds (10 kilograms), and have a brain tumor confirmed by biopsy or imaging.
- For newly diagnosed patients (Stratum 1): You have a high-grade glioma, diffuse midline glioma, or DIPG that has not been treated with radiation or surgery for this tumor.
- For patients with tumors that returned or did not respond to treatment (Stratum 2): You have a high-grade glioma, DIPG, or medulloblastoma that came back after standard therapy or is still growing after radiation.
- You must be active enough to care for yourself (score of 50% or higher on a daily activity scale) and have stable seizures (no new seizures in the last week requiring more medication).
- Your blood counts (neutrophils >1,000, platelets >100,000, hemoglobin >8) and liver/kidney function must be within certain limits.
- You cannot be pregnant or breastfeeding, and you must use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug called XRD-0394 given together with radiation therapy for people with high-grade glioma, a type of aggressive brain tumor. The goal is to see if adding this drug makes radiation more effective.
This trial tests a special type of proton radiation that treats the whole brain and spine but tries to avoid the bones of the spine, which may help reduce growth problems in children. It may be a good option for children who need this kind of radiation for a brain or spinal tumor.
This study tests a new combination of medicines (temozolomide, anlotinib, and bemarituzumab) taken during radiation therapy for children with a type of brain tumor called diffuse midline glioma. The goal is to see if this approach can help improve outcomes compared to standard treatment.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This trial tests whether a special herpes virus (G207) combined with low-dose radiation can help children with high-grade brain tumors (gliomas). The virus is injected into the tumor to attack the cancer cells while radiation helps boost the effect.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.